Abstract

In this era where health crises are increasingly prominent throughout the world, Article 31bis of the TRIPs Agreement emerges as a beacon of hope for equitable access to essential pharmaceuticals especially for under developed and developing countries. This article examines in detail, Article 31bis of the TRIPs Agreement which facilitates the export of pharmaceutical products from countries having manufacturing capacities to those lacking such capability, particularly in the context of public health emergencies such as COVID-19 pandemic. The article also focusses on the shortcomings of the provision which is further illustrated by Bolivia’s challenges in importing vaccines during the pandemic. The article discusses the ambiguity and flexibility that is inherent in Article 31bis, which may lead to inconsistencies and disputed among member states regarding its interpretation and application. In order to address these issues, the article proposes several solutions including encouragement of Regional Trade Agreements (RTAs) and the development of scientific infrastructure in developing nations. Further, the article calls for a reconsideration of data exclusivity regulations to better align with the goals of expanding access to essential medicines. Finally, the article emphasizes on the need for international cooperation and adaptability in order to enhance the effectiveness of Article 31bis, thereby ensuring equitable access to vital medicines while balancing the rights of holders of intellectual property.

Keywords